Vicore Pharma: A Game Changer in the Biotech Arena

Vicore Pharma Holding AB (publ) is set to make waves at the upcoming Van Lanschot Kempen Life Sciences Conference on April 16, 2025, in Amsterdam, Holland. The company, known for its innovative approach to respiratory and fibrotic diseases, will be represented by Hans Jeppsson, CFO, and Bertil Lindmark, CMO. This participation is more than just a conference appearance; it's a strategic move that could significantly influence investor sentiment and stock performance.

Vicore Pharma's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist currently in phase 2a development for idiopathic pulmonary fibrosis (IPF). This drug has received Orphan Drug and Fast Track designation from the FDA, positioning Vicore at the forefront of IPF treatment. The global 52-week Phase 2b ASPIRE trial is underway, and any positive updates from this trial could send Vicore's stock soaring.

But Vicore isn't just about buloxibutid. Their digital therapeutic, Almee™, has received Breakthrough Device Designation from the FDA. Almee is designed to address the psychological impact of living with pulmonary fibrosis, offering a transformative approach to patient care. Any progress in the clinical development or regulatory approval of Almee could further boost investor confidence.

Financial performance and strategic initiatives are also crucial. Vicore recently completed a capital increase via an accelerated bookbuild offering of 10,000,000 new shares, generating gross proceeds of SEK 200m (c. EUR 18.3m). This capital will be used to finance the preparations of a Phase 2b trial in IPF, prepare the commercial launch of Almee™, accelerate the development of their ATRAG platform, and advance their preclinical pipeline. These strategic initiatives demonstrate Vicore's commitment to advancing its pipeline and securing the necessary financial resources to support its clinical development programs.

The conference provides a platform for Vicore to showcase its innovative pipeline and disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). This is evident from the company's lead program, buloxibutid (C21), which is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist currently in phase 2a development for IPF. By presenting at the conference, Vicore can highlight the progress and potential of this program, which has received Orphan Drug and Fast Track designation from the FDA.

The conference allows Vicore to engage with key stakeholders, including investors, industry peers, and potential partners. This engagement is crucial for securing the necessary financial resources and strategic collaborations to support its clinical development programs. For instance, Vicore recently completed a rights issue of approximately SEK 782 million (USD 75 million), which was oversubscribed by ~33%. This financing round was supported by current shareholders and new investors, including the global biopharmaceutical company sanofi. The funds raised from this rights issue will ensure that Vicore is fully funded through the ASPIRE trial with additional cash runway.

The conference provides an opportunity for Vicore to demonstrate its unique expertise in ATRAG chemistry and biology, which is fueling its pipeline with several new therapies across additional potential indications. This expertise is a key differentiator for Vicore in the competitive biotech industry and can attract potential partners and investors.

Lastly, the conference aligns with Vicore's goal of advancing its pipeline of innovative therapies and securing the necessary financial resources to support its clinical development programs. The successful completion of the Phase 2b ASPIRE trial and the successful financing rounds position Vicore for long-term growth and a stronger market position in the respiratory and fibrotic diseases space.